Advanced Glycation End-Products (AGEs): Receptors, Signalling Pathways, and Anti-AGE Therapies
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biomacromolecules: Proteins, Nucleic Acids and Carbohydrates".
Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 9181
Special Issue Editors
Interests: nutrigenomics, cell signaling, receptors, GPCR-receptors, chemistry and biochemistry of nucleic acids
Interests: Stab2 receptor, advanced glycation end-products, protein-ligand interactions, structural biology, Stab2 receptor, advanced glycation end-products, psychrophilic enzymes
Special Issue Information
Dear Colleagues,
Advanced glycation end-products (AGEs) constitute a complex, chemically diverse group of biomolecules formed endogenously on the course of various pathways in the human body or absorbed exogenously from diet. They are formed non-enzymatically by condensation of the carbonyl group of reducing saccharides and the free amine group of nucleic acids, proteins, or lipids. Unstable intermediates are further rearranged, yielding a group of reactive carbonyls and irreversible, stable end-products. The most investigated examples of AGEs include Nε-(carboxymethyl)lysine (CML), Nε-(1-carboxyethyl)lysine (CEL), pentosidine, crossline, arginine pyrimidine, and others. Levels of specific glycated proteins, such as circulating glycated hemoglobin (HbA1c), serve as reliable biomarkers of adverse states like hyperglycemic states, insulin resistance, and diabetes mellitus (DM).
AGEs are recognized by several cellular receptors, including the Receptor for AGEs (RAGE), AGE-R1/OST-48, AGE-R2/80K-H, AGE-R3/galectin-3, and scavenger receptors (Stab1, Stab2, LOX1, CD36, SR-AI, SR-BI). The insight into structural aspects of AGE binding is minimal, and no receptor-ligand crystal structures are known. Only one solution NMR structure with CEL peptide for the primary receptor, RAGE, is currently available.
Upon binding to the receptor, AGEs trigger many signalling pathways related to inflammation and oxidative stress. The number of publications reporting the evidence of their involvement in many physiological and pathological processes is steadily growing. They have been implicated in several lifestyle-related diseases, including DM and its complications, cancer, renal, neurodegenerative, and cardiovascular diseases.
The strategies against the deleterious impact of AGEs rely either on natural products or synthetic compounds and can have diverse mechanisms of action. One of the approaches is the scavenging of AGEs; the others aim to block the receptors of these biomolecules or reduce their formation in the human body. Although many pharmacologic anti-AGE treatments have been recently reported, their efficacy remains to be evaluated in clinical trials.
The goal of this Special Issue is to collect experimental papers and reviews that enhance the understanding of AGE-receptor binding, the signalling pathways they activate, and anti-AGE therapies. We look forward to receiving your contributions.
Prof. Dr. Maria Koziołkiewicz
Dr. Aleksandra Twarda-Clapa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- advanced glycation end-products
- AGEs, AGE receptors
- anti-AGE therapies
- RAGE
- scavenger receptors
- AGE-related diseases
- signalling pathways
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
